Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
Open Access
- 14 August 2013
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 31 (43), 4968-4974
- https://doi.org/10.1016/j.vaccine.2013.08.006
Abstract
No abstract availableKeywords
Funding Information
- Novartis Vaccines
This publication has 22 references indexed in Scilit:
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProceedings of the National Academy of Sciences, 2010
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37Infection and Immunity, 2009
- Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- MeNZB™: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strainVaccine, 2005
- Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cellsMolecular Microbiology, 2004
- Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870The Journal of Experimental Medicine, 2003
- NadA, a Novel Vaccine Candidate of Neisseria meningitidis The Journal of Experimental Medicine, 2002
- Meningococcal VaccinesInfectious Disease Clinics of North America, 2001
- ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITISThe Lancet, 1983